CXCR3 and myeloid sarcoma: However, concurrent upregulation of a set of CXCR3 and CCR2 ligand chemokines has not previously been reported in MS patients on a long-term IFNβ treatment [16,17,20-22], suggesting that this phenomenon is an immediate early but transient event in vivo.